Article
Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
The Journal of investigative dermatology - 1 Dec 2020
Adam Christian, Fusi Lorenza, Weiss Neele, Goller Simon G, Meder Katharina, Frings Verena G, Kneitz Hermann, Goebeler Matthias, Houben Roland, Schrama David, Schmidt Marc
Abstract excerpt
Cutaneous melanoma is a highly malignant tumor typically driven by somatic mutation in the oncogenes BRAF or NRAS, leading to uncontrolled activation of the MEK/ERK MAPK pathway. Despite the availability of immunotherapy, MAPK pathway‒targeting regimens are still a valuable treatment option for BRAF-mutant melanoma. Unfortunately, patients with NRAS mutation do not benefit from such therapies owing to the lack of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.